 Home > Medical News > Latest Medical News > Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint

Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint

 Last Update: 2021-11-14
 Source: Internet
 Author: User

Tags

3 4 1 8

c3 cycle

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Novartis announced that its potential "first-in-class" oral factor B inhibitor iptacopan (LNP023) has reached its primary clinical endpoint in a phase 2 clinical trial for the treatment of patients with C3 glomerulopathy (C3G).

C3G is a rare and severe form of primary glomerulonephritis, which is characterized by complement disorders

Iptacopan is an oral specific alternative complement pathway factor B inhibitor

▲Factor B inhibitors can be used to treat a variety of complement-driven nephropathy (picture source: Novartis official website)

In this phase 2 clinical trial of two patient cohorts, C3G patients who had not yet received a kidney transplant had a 45% reduction in proteinuria level compared with baseline after 12 weeks of treatment with iptacopan (p=0.

In addition, both patient cohorts showed persistent and strong inhibition of alternative complement pathway activity

Reference materials:

[1] Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G).

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.